Treatment of MS patients with biological drugs designed to suppress the induction, migration, or function of CD4+ T cells, such as natalizumab, come with an increased risk of infection, in particular progressive multifocal leukoencephalopathy (PML) (68). Here, CD4 is linked to myeloid sarcoma.